Doping drug gives no edge to serious cyclists in study
June 30, 2017
The blood booster at the heart of the Lance Armstrong doping scandal does not improve real-world cycling performance, according to the most rigorous study yet of how the protein EPO affects athletes.
The results, published Thursday in the journal Lancet Haematology , may convince some to pay more attention to the harms of supposed performance-enhancing drugs by punching holes in the myths surrounding them, researchers said.
Dutch scientists staged a bike race up a mountain to study whether erythropoietin (EPO) lives up to its reputation, transporting a large group of avid cyclists to southern...
For access to this article please
sign in or
subscribe.
Reader Comments(0)